+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID06648434

Phase 1 Study of MK2 Inhibitor Zunsemetinib Combined with mFOLFIRINOX Chemotherapy for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Led by Washington University School of Medicine · Updated on 2026-04-30

51

Participants Needed

1

Research Sites

152 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether inhibiting MK2 can improve the effectiveness of mFOLFIRINOX chemotherapy in patients with untreated metastatic pancreatic ductal adenocarcinoma PDAC. This Phase I trial focuses on determining the right dose of the MK2 inhibitor, zunsemetinib, combined with mFOLFIRINOX, a chemotherapy regimen including oxaliplatin, irinotecan, leucovorin, and 5-FU. Participants receive zunsemetinib orally once or twice daily depending on the dose level assigned during the dose escalation phase. The chemotherapy mFOLFIRINOX is given intravenously every two weeks in cycles consisting of oxaliplatin, irinotecan, leucovorin, and a continuous infusion of 5-FU over 46 hours. The trial includes a dose escalation phase to find the recommended Phase II dose followed by a dose expansion phase to further evaluate this combination treatment. During the study, participants are monitored for dose-limiting toxicities and adverse events. Researchers measure treatment responses such as progression-free survival, overall survival, disease control, and tumor marker changes over time. Blood samples are collected to study drug levels and metabolites. The study involves regular assessments over approximately 12 months of treatment and up to 3 years of follow-up to track long-term outcomes and safety.

CONDITIONS

Brief Title

MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Research Team

M

Moh'd Khushman, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here